{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:49:50Z","timestamp":1794415790166,"version":"4.9.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00125-017-4318-z","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T02:13:29Z","timestamp":1501726409000},"page":"1566-1576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":966,"title":["Metformin: historical overview"],"prefix":"10.1007","volume":"60","author":[{"given":"Clifford J.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"4318_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pdi.606","volume":"21","author":"CJ Bailey","year":"2004","unstructured":"Bailey CJ, Day C (2004) Metformin: its botanical background. Pract Diabetes Int 21:115\u2013117","journal-title":"Pract Diabetes Int"},{"key":"4318_CR2","unstructured":"Culpeper N (1995) Culpeper\u2019s complete herbal: a book of natural remedies for ancient ills. Wordsworth Editions Ltd, Ware, Hertfordshire p335. Available from https:\/\/books.google.co.uk\/books?id=aGih_JZtPvoC&pg=PA335&lpg=PA335&dq=galega+culpeper+herbal&source=bl&ots=77gExCABa_&sig=wV0BcjUm_RS8F6ZRMjo8N8F6zgU&hl=en&sa=X&ved=0ahUKEwiPw_fJ6YzSAhUBJcAKHV4EB2kQ6AEIQTAH#v=onepage&q=galega%20culpeper%20herbal&f=false . Accessed 13 Feb 2017"},{"key":"4318_CR3","unstructured":"Hill J (1772). The vegetable system. Or the internal structure and the life of plants; their parts, and nourishment, explained; their classes, orders, genera, and species, ascertained, and described; in a methods altogether new: comprehending an artificial index, and a natural system. With figures of all the plants; designed and engraved by the author. The whole from nature only. Vol. XXI, containing plants and four-petal\u2019d irregular flowers. London, p54"},{"key":"4318_CR4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/1478271520053503010","volume":"35","author":"DR Hadden","year":"2005","unstructured":"Hadden DR (2005) Goat\u2019s rue\u2014French lilac \u2013 Italian fitch \u2013 Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb 35:258\u2013260","journal-title":"J R Coll Physicians Edinb"},{"key":"4318_CR5","unstructured":"Galega officinalis. Available from https:\/\/en.wikipedia.org\/wiki\/Galega_officinalis . Accessed 27 Feb 2017"},{"key":"4318_CR6","first-page":"p79","volume-title":"Glucophage: serving diabetology for 40 years","author":"C Pasik","year":"1997","unstructured":"Pasik C (1997) Diabetes and the biguanides: the mystery of each. In: Pasik C (ed) Glucophage: serving diabetology for 40 years. Groupe Lipha, Lyon, p79"},{"key":"4318_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9258(18)86579-6","volume":"33","author":"CK Watanabe","year":"1918","unstructured":"Watanabe CK (1918) Studies in the metabolic changes induced by administration of guanidine bases. Influence of injected guanidine hydrochloride upon blood sugar content. J Biol Chem 33:253\u2013265","journal-title":"J Biol Chem"},{"key":"4318_CR8","doi-asserted-by":"crossref","unstructured":"Frank E, Nothmann M, Wagner A (1926) \u00dcber synthetisch dargestellte K\u00f6rper mit insulinartiger Wirkung auf den normalen und diabetischen Organismus. Klin Wchnschr 5:2100\u20132107 [article in German]","DOI":"10.1007\/BF01736560"},{"key":"4318_CR9","unstructured":"Simonnet H, Tanret G (1927). Sur les proprietes hypoglycemiantes du sulfate de galegine. Bull Soc Chim Biol Paris, 8 [article in French]"},{"key":"4318_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0021-9258(18)83816-9","volume":"81","author":"F Bischoff","year":"1928","unstructured":"Bischoff F, Sahyun M, Long ML (1928) Guanidine structure and hypoglycemia. J Biol Chem 81:325\u2013349","journal-title":"J Biol Chem"},{"key":"4318_CR11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF01862957","volume":"125","author":"H Muller","year":"1927","unstructured":"Muller H, Reinwein H (1927) Zur Pharmakologie des Galegins. Arch Exp Path Pharmacol 125:212\u2013228 [article in German]","journal-title":"Arch Exp Path Pharmacol"},{"key":"4318_CR12","first-page":"901","volume":"17","author":"IM Rabinowiz","year":"1927","unstructured":"Rabinowiz IM (1927) Observations on the use of synthalin in the treatment of diabetes mellitus. Can Med Assoc J 17:901\u2013904","journal-title":"Can Med Assoc J"},{"key":"4318_CR13","unstructured":"Leclerc H. Le galega. Presse Med 1928, 22 d\u00e9cembre [article in French]"},{"key":"4318_CR14","first-page":"3","volume-title":"Metformin\u2014the gold standard: a scientific handbook","author":"HCS Howlett","year":"2007","unstructured":"Howlett HCS, Bailey CJ (2007) Galegine and antidiabetic plants. In: Bailey CJ, Campbell IW, JCN C et al (eds) Metformin\u2014the gold standard: a scientific handbook. Wiley, Chichester, pp 3\u20139"},{"key":"4318_CR15","unstructured":"Parturier H, Hugnot G (1935). Le galega dans le traitement du diab\u00e8te. Massons, Paris [article in French]"},{"key":"4318_CR16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/cber.187901201219","volume":"12","author":"B Rathke","year":"1879","unstructured":"Rathke B (1879) Uber Biguanid. Ber Dtsch Chem Ges 12:776\u2013784 [article in German]","journal-title":"Ber Dtsch Chem Ges"},{"key":"4318_CR17","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1039\/CT9222101790","volume":"121","author":"EA Werner","year":"1922","unstructured":"Werner EA, Bell J (1922) The preparation of methylguanidine, and of \u03b2\u03b2-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans 121:1790\u20131794","journal-title":"J Chem Soc Trans"},{"key":"4318_CR18","doi-asserted-by":"crossref","unstructured":"Hesse G, Taubmann G (1929) Die Wirkung des Biguanids und seiner Derivate auf den Zuckerstoffwechsel. Arch Exp Path Pharmacol 142:290\u2013308 [article in German]","DOI":"10.1007\/BF02000097"},{"key":"4318_CR19","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cber.19290620605","volume":"62","author":"KH Slotta","year":"1929","unstructured":"Slotta KH, Tschesche R (1929) Uber Biguanide. Die blutzuckersenkende Wirkung der Biguanides. Ber Dtsch Chem Ges 62:1398\u20131405 [article in German]","journal-title":"Ber Dtsch Chem Ges"},{"key":"4318_CR20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/00034983.1945.11685237","volume":"39","author":"FHS Curd","year":"1945","unstructured":"Curd FHS, Davey DG, Rose FL (1945) Studies on synthetic antimalarial drugs. Some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ann Trop Med Parasitol 39:208\u2013216","journal-title":"Ann Trop Med Parasitol"},{"key":"4318_CR21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-3565(25)00587-7","volume":"91","author":"KK Chen","year":"1947","unstructured":"Chen KK, Anderson RC (1947) The toxicity and general pharmacology of N1-p-chlorophenyl-N5-isopropyl biguanide. J Pharmacol Exp Ther 91:157\u2013160","journal-title":"J Pharmacol Exp Ther"},{"key":"4318_CR22","first-page":"287","volume":"26","author":"EY Garcia","year":"1950","unstructured":"Garcia EY (1950) Flumamine, a new synthetic analgesic and anti-flu drug. J Philippine Med Assoc 26:287\u2013293","journal-title":"J Philippine Med Assoc"},{"key":"4318_CR23","first-page":"29","volume-title":"Glucophage: serving diabetology for 40 years","author":"C Pasik","year":"1997","unstructured":"Pasik C (1997) Jean Sterne: a passion for research. In: Pasik C (ed) Glucophage: serving diabetology for 40 years. Lyon, Groupe Lipha, pp 29\u201331"},{"key":"4318_CR24","unstructured":"Sterne J (1957) Du nouveau dans les antidiab\u00e9tiques. La NN dimethylamine guanyl guanidine (N.N.D.G.) Maroc Med 36:1295\u20131296 [article in French]"},{"key":"4318_CR25","first-page":"650","volume":"13","author":"J Sterne","year":"1958","unstructured":"Sterne J (1958) Blood sugar-lowering effect of 1,1-dimethylbiguanide. Therapie 13:650\u2013659 article in French","journal-title":"Therapie"},{"key":"4318_CR26","first-page":"625","volume":"14","author":"J Sterne","year":"1959","unstructured":"Sterne J (1959) Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage). Therapie 14:625\u2013630 [article in French]","journal-title":"Therapie"},{"key":"4318_CR27","first-page":"599","volume":"113","author":"J Sterne","year":"1963","unstructured":"Sterne J (1963) Report on 5-years\u2019 experience with dimethylbiguanide (metformin, glucophage) in diabetic therapy. Wien Med Wochenschr 113:599\u2013602 [article in German]","journal-title":"Wien Med Wochenschr"},{"key":"4318_CR28","first-page":"171","volume":"12","author":"J Sterne","year":"1964","unstructured":"Sterne J, Hirsch C (1964) Experimental basis for combined treatment of diabetes with the biguanide-sulfonamide association. Diabete 12:171\u2013175 [article in French]","journal-title":"Diabete"},{"key":"4318_CR29","first-page":"17","volume":"72","author":"J Sterne","year":"1964","unstructured":"Sterne J (1964) Mechanism of action of antidiabetic biguanides. Presse Med 72:17\u201319 [article in French]","journal-title":"Presse Med"},{"key":"4318_CR30","first-page":"193","volume-title":"Oral hypoglycemic agents","author":"J Sterne","year":"1969","unstructured":"Sterne J (1969) Pharmacology and mode of action of the hypoglycemic guanidine derivatives. In: Campbell GD (ed) Oral hypoglycemic agents. Academic Press, London, pp 193\u2013245"},{"key":"4318_CR31","unstructured":"Sterne J, Duval D, Junien JL (1979). Aspects of pharmacology and mechanisms of action. In: Cudwoth AG (ed) Metformin: current aspects and future developments. Research and Clinical Forums, Vol. 1, Tunbridge Wells, pp 13\u201320"},{"key":"4318_CR32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3181\/00379727-95-23163","volume":"95","author":"G Ungar","year":"1957","unstructured":"Ungar G, Freedman L, Shapiro SL (1957) Pharmacological studies of a new oral hypoglycemic drug. Proc Soc Exp Biol Med 95:190\u2013192","journal-title":"Proc Soc Exp Biol Med"},{"key":"4318_CR33","first-page":"880","volume":"108","author":"A Beringer","year":"1958","unstructured":"Beringer A (1958) Zur Behandlung der Zuckerkrankheiten mit Biguaniden. Wien Med Wschr 108:880\u2013882 [article in German]","journal-title":"Wien Med Wschr"},{"key":"4318_CR34","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1021\/ja01523a060","volume":"81","author":"SL Shapiro","year":"1959","unstructured":"Shapiro SL, Parrino VA, Freedman L (1959) Hypoglycemic agents. III.1\u20143N1-alkyl- and aralkylbiguanides. J Am Chem Soc 81:3728\u20133736","journal-title":"J Am Chem Soc"},{"key":"4318_CR35","first-page":"439","volume":"29","author":"R Beckmann","year":"1971","unstructured":"Beckmann R (1971) Biguanide (Experimenteller Teil). Handb Exp Pharmacol 29:439\u2013596 [article in German]","journal-title":"Handb Exp Pharmacol"},{"key":"4318_CR36","first-page":"765","volume":"67","author":"E Azerad","year":"1959","unstructured":"Azerad E, Lubetzki J (1959) Treatment of diabetes with N,N-dimethyl diguanide (LA6023). Presse Med 67:765\u2013767 [article in French]","journal-title":"Presse Med"},{"key":"4318_CR37","first-page":"773","volume":"80","author":"JB McKendry","year":"1959","unstructured":"McKendry JB, Kuwayti K, Rado PP (1959) Clinical experience with DBI (phenformin) in the management of diabetes. Can Med Assoc J 80:773\u2013778","journal-title":"Can Med Assoc J"},{"key":"4318_CR38","unstructured":"Mehnert H, Seitz W (1958) Weitere Ergebnisse der Diabetesbehandlung mit blutzuckersenkenden Biguaniden. M\u00fcnch Med Wochenschr 100:1849\u20131851 [article in German]"},{"key":"4318_CR39","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1749-6632.1968.tb27744.x","volume":"148","author":"WJ Butterfield","year":"1968","unstructured":"Butterfield WJ (1968) The effects of phenformin on peripheral glucose utilization and insulin action in obesity and diabetes mellitus. Ann N Y Acad Sci 148:724\u2013733","journal-title":"Ann N Y Acad Sci"},{"key":"4318_CR40","first-page":"148","volume":"9","author":"G Sch\u00e4fer","year":"1983","unstructured":"Sch\u00e4fer G (1983) Biguanides: a review of history, pharmacodynamics and therapy. Diabete Metab 9:148\u2013163","journal-title":"Diabete Metab"},{"key":"4318_CR41","first-page":"233","volume":"5","author":"LS Hermann","year":"1979","unstructured":"Hermann LS (1979) Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 5:233\u2013245","journal-title":"Diabete Metab"},{"key":"4318_CR42","doi-asserted-by":"crossref","unstructured":"Clarke BF, Duncan LJP (1968) Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 291:123\u2013126","DOI":"10.1016\/S0140-6736(68)92726-8"},{"key":"4318_CR43","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/bmj.2.6102.1576","volume":"275","author":"B Clarke","year":"1977","unstructured":"Clarke B, Campbell IW (1977) Comparison of metformin and chlorpropamide in non-obese maturity-onset diabetic uncontrolled on diet. Br Med J 275:1576\u20131578","journal-title":"Br Med J"},{"issue":"Suppl 1","key":"4318_CR44","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1002\/dmr.5610110509","volume":"11","author":"IW Campbell","year":"1995","unstructured":"Campbell IW, Howlett HC (1995) Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Res Rev 11(Suppl 1):S57\u2013S62","journal-title":"Diabetes Metab Res Rev"},{"key":"4318_CR45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/diacare.15.6.755","volume":"15","author":"CJ Bailey","year":"1992","unstructured":"Bailey CJ (1992) Biguanides and NIDDM. Diabetes Care 15:755\u2013772","journal-title":"Diabetes Care"},{"key":"4318_CR46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/bmj.2.5158.1005","volume":"2","author":"RS Walker","year":"1959","unstructured":"Walker RS, Linton AL (1959) Phenethylbiguanide: a dangerous side effect. Br Med J 2:1005\u20131006","journal-title":"Br Med J"},{"key":"4318_CR47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01263444","volume":"14","author":"D Luft","year":"1978","unstructured":"Luft D, Schmulling RM, Eggstein M (1978) Lactic acidosis in biguanide-treated diabetics. Diabetologia 14:75\u201387","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"4318_CR48","first-page":"65","volume":"24","author":"University Group Diabetes Program","year":"1975","unstructured":"University Group Diabetes Program (1975) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Evaluation of phenformin therapy. Diabetes 24(Suppl 1):65\u2013184","journal-title":"Diabetes"},{"key":"4318_CR49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01263443","volume":"14","author":"M Nattrass","year":"1978","unstructured":"Nattrass M, Alberti KGMM (1978) Biguanides. Diabetologia 14:71\u201374","journal-title":"Diabetologia"},{"key":"4318_CR50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0950-351X(88)80043-0","volume":"2","author":"CJ Bailey","year":"1988","unstructured":"Bailey CJ, Nattrass M (1988) Treatment\u2014metformin. Balli\u00e8re\u2019s Clin Endocrinol Metab 2:455\u2013476","journal-title":"Balli\u00e8re\u2019s Clin Endocrinol Metab"},{"key":"4318_CR51","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/11536790-000000000-00000","volume":"33","author":"JD Lalau","year":"2010","unstructured":"Lalau JD (2010) Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 33:727\u2013740","journal-title":"Drug Saf"},{"key":"4318_CR52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(80)91604-9","volume":"315","author":"RR Shah","year":"1980","unstructured":"Shah RR, Oates NS, Idle JR, Smith RL (1980) Genetic impairment of phenformin metabolism. Lancet 315:1147","journal-title":"Lancet"},{"key":"4318_CR53","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diab.30.8.644","volume":"30","author":"E Bosisio","year":"1981","unstructured":"Bosisio E, Kienle MG, Galli G et al (1981) Defective hydroxylation of phenformin as a determinant of drug toxicity. Diabetes 30:644\u2013649","journal-title":"Diabetes"},{"key":"4318_CR54","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","volume":"37","author":"RA DeFronzo","year":"1988","unstructured":"DeFronzo RA (1988) The triumvirate: \u03b2-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667\u2013687","journal-title":"Diabetes"},{"key":"4318_CR55","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595\u20131607","journal-title":"Diabetes"},{"key":"4318_CR56","first-page":"23","volume-title":"Metformin, the gold standard. A scientific handbook","author":"HCS Howlett","year":"2007","unstructured":"Howlett HCS, Bailey CJ (2007) Metformin: a chemical perspective. In: Bailey CJ, Campbell IW, Chan JCN et al (eds) Metformin, the gold standard. A scientific handbook. Wiley, Chichester, pp 23\u201328"},{"key":"4318_CR57","first-page":"212","volume":"12","author":"CJ Bailey","year":"1986","unstructured":"Bailey CJ, Puah JA (1986) Effect of metformin on glucose metabolism in mouse soleus muscle. Diabete Metab 12:212\u2013218","journal-title":"Diabete Metab"},{"key":"4318_CR58","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/0006-2952(88)90617-X","volume":"37","author":"N Wollen","year":"1988","unstructured":"Wollen N, Bailey CJ (1988) Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin. Biochem Pharmacol 37:4353\u20134358","journal-title":"Biochem Pharmacol"},{"key":"4318_CR59","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1476-5381.1992.tb09093.x","volume":"105","author":"CJ Bailey","year":"1992","unstructured":"Bailey CJ, Wilcock C, Day C (1992) Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 105:1009\u20131013","journal-title":"Br J Pharmacol"},{"key":"4318_CR60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/00498259409043220","volume":"24","author":"C Wilcock","year":"1994","unstructured":"Wilcock C, Bailey CJ (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24:49\u201357","journal-title":"Xenobiotica"},{"key":"4318_CR61","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1476-5381.1994.tb13128.x","volume":"112","author":"CJ Bailey","year":"1994","unstructured":"Bailey CJ, Mynett KJ, Page T (1994) Importance of the intestine as a site of metformin-stimulated glucose utilization. Brit J Pharmacol 112:671\u2013675","journal-title":"Brit J Pharmacol"},{"issue":"Suppl 1","key":"4318_CR62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","volume":"58","author":"NF Wiernsperger","year":"1999","unstructured":"Wiernsperger NF, Bailey CJ (1999) The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 58(Suppl 1):31\u201339","journal-title":"Drugs"},{"key":"4318_CR63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","volume":"333","author":"RA DeFronzo","year":"1995","unstructured":"DeFronzo RA, Goodman AM, Multicenter Metformin Study Group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541\u2013549","journal-title":"N Engl J Med"},{"key":"4318_CR64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","volume":"334","author":"CJ Bailey","year":"1996","unstructured":"Bailey CJ, Turner RC (1996) Drug therapy: metformin. N Engl J Med 334:574\u2013579","journal-title":"N Engl J Med"},{"key":"4318_CR65","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1185\/030079904125003278","volume":"20","author":"L Blonde","year":"2004","unstructured":"Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ (2004) Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets\u2014results of a retrospective cohort study. Curr Med Res Opin 20:565\u2013572","journal-title":"Curr Med Res Opin"},{"key":"4318_CR66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/14746514040040041101","volume":"4","author":"J Davidson","year":"2004","unstructured":"Davidson J, Howlett H (2004) New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis 4:273\u2013277","journal-title":"Br J Diabetes Vasc Dis"},{"key":"4318_CR67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1463-1326.2002.00211.x","volume":"4","author":"AJ Garber","year":"2002","unstructured":"Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D (2002) Simultaneous glyburide\/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 4:201\u2013208","journal-title":"Diabetes Obes Metab"},{"key":"4318_CR68","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1463-1326.2008.00993.x","volume":"11","author":"CJ Bailey","year":"2009","unstructured":"Bailey CJ, Day C (2009) Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 11:527\u2013533","journal-title":"Diabetes Obes Metab"},{"key":"4318_CR69","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854\u2013865","journal-title":"Lancet"},{"key":"4318_CR70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/14746514070070050201","volume":"7","author":"NF Wiernsperger","year":"2007","unstructured":"Wiernsperger NF (2007) 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis 7:204\u2013210","journal-title":"Br J Diabetes Vasc Dis"},{"key":"4318_CR71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10557-008-6092-0","volume":"22","author":"CJ Bailey","year":"2008","unstructured":"Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drug Ther 22:215\u2013224","journal-title":"Cardiovasc Drug Ther"},{"key":"4318_CR72","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1464-5491.2005.01448.x","volume":"22","author":"JA Johnson","year":"2005","unstructured":"Johnson JA, Simpson SH, Toth EL, Majumdar SR (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497\u2013502","journal-title":"Diabet Med"},{"key":"4318_CR73","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","volume":"28","author":"D Eurich","year":"2005","unstructured":"Eurich D, Majumdar SR, FA MA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345\u20132351","journal-title":"Diabetes Care"},{"key":"4318_CR74","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589","journal-title":"N Engl J Med"},{"key":"4318_CR75","unstructured":"International Diabetes Federation Clinical Guidelines Task Force (2012). Global guideline for type 2 diabetes. Available from www.idf.org\/e-library\/guidelines\/79-global-guideline-for-type-2-diabetes . Accessed 10 May 2017"},{"key":"4318_CR76","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes. Diabetologia 58:429\u2013442","journal-title":"Diabetologia"},{"key":"4318_CR77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","volume":"23","author":"AJ Garber","year":"2017","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI et al (2017) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142017 executive summary. Endocr Pract 23:207\u2013238","journal-title":"Endocr Pract"},{"key":"4318_CR78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M16-1860","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Barry MJ, Humphrey LL, Forciea MA for the Clinical Guidelines Committee of the American College of Physicians (2017) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:279\u2013290","journal-title":"Ann Intern Med"},{"key":"4318_CR79","unstructured":"World Health Organization (2015). WHO model list of essential medicines. Available from www.who.int\/medicines\/publications\/essentialmedicines\/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 . Accessed 10 Feb 2017"},{"key":"4318_CR80","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(61)92002-5","volume":"1","author":"AW Ferguson","year":"1961","unstructured":"Ferguson AW, De La Harpe PL, Farquhar JW (1961) Dimethyl biguanide in the treatment of diabetic children. Lancet 1:1367\u20131369","journal-title":"Lancet"},{"key":"4318_CR81","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393\u2013403","journal-title":"N Engl J Med"},{"key":"4318_CR82","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","volume":"75","author":"U Hostalek","year":"2015","unstructured":"Hostalek U, Gwilt M, Hildemann S (2015) Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 75:1071\u20131094","journal-title":"Drugs"},{"key":"4318_CR83","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","volume":"358","author":"JA Rowan","year":"2008","unstructured":"Rowan JA, Hague WM, Gao W, Battin MR, Moore MP for the MiG Trial Investigators (2008) Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 358:2003\u20132015","journal-title":"N Engl J Med"},{"key":"4318_CR84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMct0707092","volume":"358","author":"JE Nestler","year":"2008","unstructured":"Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358:47\u201354","journal-title":"N Engl J Med"},{"key":"4318_CR85","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","volume":"284","author":"C Hadigan","year":"2000","unstructured":"Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S (2000) Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284:472\u2013477","journal-title":"JAMA"},{"key":"4318_CR86","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1742-1241.2002.tb11327.x","volume":"56","author":"T Tankova","year":"2002","unstructured":"Tankova T, Koev D, Dakovska L, Kirilov G (2002) Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract 56:578\u2013581","journal-title":"Int J Clin Pract"},{"key":"4318_CR87","first-page":"54","volume":"2","author":"PI Moreira","year":"2014","unstructured":"Moreira PI (2014) Metformin in the diabetic brain: friend or foe? Ann Transl Med 2:54","journal-title":"Ann Transl Med"},{"key":"4318_CR88","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"JM Evans","year":"2005","unstructured":"Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304\u20131305","journal-title":"BMJ"},{"key":"4318_CR89","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","volume":"52","author":"CJ Currie","year":"2009","unstructured":"Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766\u20131777","journal-title":"Diabetologia"},{"key":"4318_CR90","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","volume":"23","author":"N Barzilai","year":"2016","unstructured":"Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA (2016) Metformin as a tool to target aging. Cell Metab 23:1060\u20131065","journal-title":"Cell Metab"},{"key":"4318_CR91","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER (2016) Metformin and the gastrointestinal tract. Diabetologia 59:426\u2013435","journal-title":"Diabetologia"},{"key":"4318_CR92","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","volume":"30","author":"AJ Scheen","year":"1996","unstructured":"Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharm 30:359\u2013371","journal-title":"Clin Pharm"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-017-4318-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4318-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4318-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:14:20Z","timestamp":1750781660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-017-4318-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["4318"],"URL":"https:\/\/doi.org\/10.1007\/s00125-017-4318-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}